According to the Cancer Genome Atlas, roughly 50% of high-grade serous ovarian cancers (HGSOC) and 10–20% of triple-negative breast cancers (TNBCs) and metastatic prostate and pancreatic cancers may harbor BRCA1/2 mutations and other aberrations in HRD, qualifying them as potential candidates for treatment with PARPis [8,9,10,11]. Here, BRCA1 is linked to triple-negative breast carcinoma.